

Indoco's Revenues Grow by 22.4% Q-o-Q and by 16.9% Y-o-Y

May 28, 2012

May, 28, 2012, Mumbai: During the fourth quarter of FY 2011-12, Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 22.4% in the revenues at Rs. 1476.6 million as compared to Rs. 1206.3 million over the same quarter last year. For the full year, the company registered a growth of 16.9% at Rs. 5601.3 million as compared to Rs. 4790.6 million over last year. The EBIDTA for the quarter stood at Rs. 246.0 million as compared to Rs. 200.4 million over the same quarter last year and the EBIDTA for the year stood at Rs. 953.9 million as compared to Rs. 770.6 million last year. The un-audited results for the fourth quarter of the financial year 2011-12 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2012.

Commenting on the performance, Ms. Aditi Panandikar, Managing Director said, "Indoco has done fairly well inspite of a slowdown in the economy. However, we have a highly optimistic view of the future and are all set to take a big leap both in Domestic as well as International Business."

Mr. Sundeep V. Bambolkar, Jt. Managing Director added, "With the required infrastructure in place, well chosen product pipeline and alliances with the top generic companies of the world, it is time for Indoco to embark on the next horizon of the success curve."

HIGHLIGHTS:

For Fourth Quarter ended March 2012 of FY 2011-12:

Net Revenues at Rs. 1476.6 million
EBIDTA at Rs. 246.0 million
Profit After Tax at Rs. 125.3 million
EPS at Rs. 10.20 (Face value of Rs.10/- per share)
EPS at Rs. 1.36 (Face value of Rs.2/- per share after split & bonus)

For the Year ended March 2012 of FY 2011-12:

Net Revenues at Rs. 5601.3 million
EBIDTA at Rs. 953.9 million
Profit After Tax at Rs. 463.4 million
EPS at Rs. 37.72 (Face value of Rs.10/- per share)
EPS at Rs. 5.03 (Face value of Rs.2/- per share after split & bonus)